Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC).
暂无分享,去创建一个
Danielle M. Enserro | R. Burger | Hong Liu | M. Birrer | A. Secord | H. Gray | R. Mannel | M. Brady | D. O’Malley | K. Tewari | M. Buechel | A. Nixon | Seyedehnafiseh Mirniaharikandehei | B. Zheng | K. Wade | K. Moore
[1] W. Tian,et al. Adipose tissue area as a predictor for the efficacy of apatinib in platinum-resistant ovarian cancer: an exploratory imaging biomarker analysis of the AEROC trial , 2020, BMC Medicine.
[2] S. Pignata,et al. Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17. , 2018 .
[3] E. Oki,et al. Low Visceral Fat Content Is a Negative Predictive Marker for Bevacizumab in Metastatic Colorectal Cancer. , 2018, Anticancer research.
[4] R. Burger,et al. Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses , 2017, Journal of the National Cancer Institute.
[5] R. Ashfaq,et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. , 2017, The Lancet. Oncology.
[6] Hong Liu,et al. A two-step convolutional neural network based computer-aided detection scheme for automatically segmenting adipose tissue volume depicting on CT images , 2017, Comput. Methods Programs Biomed..
[7] Bin Zheng,et al. Quantitative measurement of adiposity using CT images to predict the benefit of bevacizumab-based chemotherapy in epithelial ovarian cancer patients. , 2016, Oncology letters.
[8] P. Sabbatini,et al. Bevacizumab after bevacizumab in platinum-sensitive recurrent ovarian cancer: A subgroup analysis of GOG0213. , 2016 .
[9] R. Burger,et al. Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatin–paclitaxel (CP) ± bevacizumab (BEV): Results from GOG-0218. , 2016 .
[10] W. Carson,et al. Increased visceral to subcutaneous fat ratio is associated with decreased overall survival in patients with metastatic melanoma receiving anti-angiogenic therapy. , 2015, Surgical oncology.
[11] B. Goff,et al. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. , 2015, Gynecologic oncology.
[12] B. Monk,et al. Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study. , 2015, Gynecologic oncology.
[13] Jacobus Pfisterer,et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial , 2015, The Lancet. Oncology.
[14] M. Zwahlen,et al. Adiposity and cancer risk: new mechanistic insights from epidemiology , 2015, Nature Reviews Cancer.
[15] M. Parmar,et al. Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. , 2014 .
[16] K. Ding,et al. Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer. , 2014, Gynecologic oncology.
[17] A. Reuss,et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Peter J. Selby,et al. Predicting Response to Bevacizumab in Ovarian Cancer: A Panel of Potential Biomarkers Informing Treatment Selection , 2013, Clinical Cancer Research.
[19] B. Monk,et al. Outcome differences in patients with advanced epithelial ovarian, primary peritoneal and fallopian tube cancers treated with and without bevacizumab , 2013 .
[20] J. Murabito,et al. Visceral and subcutaneous fat quality and cardiometabolic risk. , 2013, JACC. Cardiovascular imaging.
[21] J. Yi,et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] B. Monk,et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. , 2011, The New England journal of medicine.
[23] Jacobus Pfisterer,et al. A phase 3 trial of bevacizumab in ovarian cancer. , 2011, The New England journal of medicine.
[24] F. Wacker,et al. Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-targeted therapy? , 2011, The oncologist.
[25] F. Ghiringhelli,et al. Visceral fat area as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with antiangiogenic agents. , 2011, The oncologist.
[26] Franck Bonnetain,et al. Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer , 2009, Gut.
[27] C. Apovian,et al. Adipose Macrophage Infiltration Is Associated With Insulin Resistance and Vascular Endothelial Dysfunction in Obese Subjects , 2008, Arteriosclerosis, thrombosis, and vascular biology.
[28] L. Tartaglia,et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. , 2003, The Journal of clinical investigation.
[29] Anil K Sood,et al. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.